EMBECTA CORP. Revenues
EMBECTA CORP. (EMBC) reported Revenues of $289.30 million for the 3-month period ending 2021-12-31, per its 10-Q filed 2022-03-16.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2022-03-16
- EMBECTA CORP. revenues for the quarter ending 2021-12-31 was $289.30M, a 1.40% increase year-over-year.
- EMBECTA CORP. revenues for the quarter ending 2020-12-31 was $285.30M.
| Period end | Revenues 3 month |
|---|---|
| 2021-12-31 | $289.30M 10-Q · filed 2022-03-16 |
| 2020-12-31 | $285.30M 10-Q · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |